About GEN inCode
GEN inCode is a company based in Manchester (United Kingdom) founded in 2018 by Jordi Puig. GEN inCode has raised $5.46 million across 4 funding rounds from investors including Downing and Maven Capital Partners. GEN inCode has completed 1 acquisition, including Abcodia. GEN inCode offers products and services including CARDIO inCode-Score, LIPID inCode, SUDD inCode, THROMBO inCode, and ROCA test. GEN inCode operates in a competitive market with competitors including Denali Therapeutics, Poseida Therapeutics, Castle Biosciences, Juno Therapeutics and Unity Biotechnology, among others.
- Headquarter Manchester, United Kingdom
- Founders Jordi Puig
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Genincode Plc
-
Annual Revenue
$3.38 M (USD)25.05as on Dec 31, 2024
-
Net Profit
-$5.55 M (USD)36.8as on Dec 31, 2024
-
EBITDA
-$6.06 M (USD)28.76as on Dec 31, 2024
-
Total Equity Funding
$5.46 M (USD)
in 4 rounds
-
Latest Funding Round
$5.07 M (USD), Post-IPO
Dec 21, 2023
-
Investors
Downing
& 1 more
-
Employee Count
Not available
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of GEN inCode
GEN inCode is a publicly listed company on the LSE with ticker symbol GENI in UK, operating in the Technology services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of GEN inCode
GEN inCode offers a comprehensive portfolio of products and services, including CARDIO inCode-Score, LIPID inCode, SUDD inCode, THROMBO inCode, and ROCA test.
Assesses cardiovascular risk using genetic and clinical data.
Evaluates genetic risks related to lipid disorders.
Analyzes genetic factors for sudden death risk.
Identifies thrombosis-related genetic risks.
Provides risk assessment for ovarian cancer.
People of GEN inCode
Unlock access to complete
Funding Insights of GEN inCode
GEN inCode has successfully raised a total of $5.46M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $5.07 million completed in December 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in GEN inCode
GEN inCode has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Downing and Maven Capital Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Multiple sectors are targeted for private equity investments.
|
Locked | Locked | Locked | |
|
Inheritance tax relief, funds, and bonds are provided across sectors.
|
Locked | Locked | Locked |
Investor details for GEN inCode
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by GEN inCode
GEN inCode has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Abcodia.
Investment portfolio details for GEN inCode
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Provides ROCA test for early ovarian cancer screening and clinician resources.
|
Locked | Locked | 2010 | Locked |
Complete acquisition details for GEN inCode
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - GEN inCode
Detailed financials for GEN inCode
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Gen Incode Comparisons
Peer comparison for GEN inCode
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of GEN inCode
GEN inCode operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Denali Therapeutics, Poseida Therapeutics, Castle Biosciences, Juno Therapeutics and Unity Biotechnology, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| Locked | Locked | Locked |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| Locked | Locked | Locked |
Precision diagnostic and prognostic tests are developed by Castle Biosciences.
|
|
| Locked | Locked | Locked |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for aging diseases are developed by targeting senescent cells.
|
|
| Locked | Locked | Locked |
Diagnostic services are provided through laboratories and radiology units.
|
Detailed competitors of GEN inCode
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Gen Incode
Complete news archive for GEN inCode
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about GEN inCode
GEN inCode was founded in 2018 and raised its 1st funding round 2 years after it was founded.
GEN inCode is headquartered in Manchester, United Kingdom. It is registered at Manchester, Greater Manchester, United Kingdom.
GEN inCode is a funded company, having raised a total of $5.46M across 4 funding rounds to date.
Annual revenue of GEN inCode is $3.38M as on Dec 31, 2024.
Founded in 2018 and based in Manchester, United Kingdom, GEN inCode operates in the precision medicine sector focused on cardiovascular health. Solutions for preventing and treating cardiovascular disease risks are provided through algorithms and machine learning models. These enable accurate assessment of patients clinical and genetic risks by healthcare professionals. The companys domain is genincode.com.
GEN inCode's top competitors include Juno Therapeutics, Poseida Therapeutics and Denali Therapeutics.
GEN inCode offers CARDIO inCode-Score, LIPID inCode, SUDD inCode, THROMBO inCode, and ROCA test.
Yes, GEN inCode is publicly traded on LSE under the ticker symbol GENI.
GEN inCode has made 1 acquisition, including Abcodia.
GEN inCode has 2 investors. Key investors include Downing, and Maven Capital Partners.
The ticker symbol of GEN inCode is GENI on LSE.